Shiv Lal Soni

Dr. Shiv Lal Soni


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2020 in Journal of Medical Systems
Verified
Journal Article
Open access
PDF file
BNB Naveen Naik
B Naveen Naik
RGRekha Gupta
Rekha Gupta
ASAjay Singh
Ajay Singh
SSShiv Lal Soni
Shiv Lal Soni
GPG D Puri
G D Puri

1 January 2019 in Anesthesia: Essays and Researches
Verified
Journal Article
Open access
SSShiv Lal Soni
Shiv Lal Soni
KKKamal Kajal
Kamal Kajal
DDDivya Dharmu
Divya Dharmu
IBIshwar Bhukkal
Ishwar Bhukkal
SYSandhya Yaddanapudi
Sandhya Yaddanapudi
ASAnkush Singla
Ankush Singla
J Indian Prosthodont Soc, Official publication of Indian Prosthodontic Society

1 January 2022 in Indian Journal of Medical Research
Verified
Journal Article
Open access
SKSukhpal Kaur
Sukhpal Kaur
ASAjay Singh
Ajay Singh
SSSushma Saini
Sushma Saini
LRLatika Rohilla
Latika Rohilla
JKJASVIR KAUR
JASVIR KAUR
GPG.D. Puri
G.D. Puri
Background & objectives: The safety of the ChAdOx1 nCoV-19 vaccine is a cause of concern for many who have been vaccinated. The people have multiple concerns and fear regarding the adverse events of the vaccine. Thus, this study was undertaken to establish the safety profile of ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) among the healthcare professionals. Methods: This was a descriptive cross-sectional survey. After taking clearance from the institutional ethics committee 1500 healthcare professionals, who had their vaccination in the past two weeks were selected. They were provided with an online survey proforma regarding adverse events following immunization (AEFIs) of COVID-19 vaccine developed using google forms with an informed consent form affixed to it. Results: A total of 1036 individuals participated in the study. The mean and median (inter quartile range) age of the participants was 37.7 ±11.25 and 35 (29-46) yr, respectively. Of these, 52.1 per cent were female, 29.3 per cent were doctors, 33.4 per cent were nurses and 9.5 per cent were paramedical staff. Forty six per cent participants experienced one or more minor AEFIs such as pain, tenderness, redness, etc. at the injection site. Fatigue (31.75%), generalized feeling of unwell (28.57%), muscle pain (23.16%) and fever (21.71%) were the most commonly reported systemic AEFIs followed by headache (20.07%), dizziness (10.03%) and joint pains (15.25%). Most of them experienced these AEFIs within 24 h of the first dose of administration. About 42 per cent of the participants took oral antipyretics/analgesics for managing the AEFIs. Interpretation & conclusions: ChAdOx1 nCoV-19 Corona Virus Vaccine was found to be associated with mild local and systemic AEFIs that were more common after the first dose as compared to the second dose. There adverse events could be dealt with oral over-the-counter medications, with no requirement of hospitalization.

17 March 2021 in Journal of Neurosurgical Anesthesiology
Verified
Journal Article
Closed access
RRRagula Mbbs Rajkiran
Ragula Mbbs Rajkiran
SSShiv Lal Soni
Shiv Lal Soni
KJKiran Dm Jangra
Kiran Dm Jangra
HBHemant Dm Bhagat
Hemant Dm Bhagat
ASAjay Singh
Ajay Singh
NKNarender Dm Kaloria
Narender Dm Kaloria
Background: The use of nonsteroidal anti-inflammatory drugs in neurosurgery remains controversial because of potential risk of hematoma formation secondary to platelet dysfunction. This study aimed to investigate the efficacy and safety of diclofenac compared with paracetamol for the management of postcraniotomy pain. Methods: In all, 110 adult patients undergoing craniotomy for supratentorial tumors were randomized to receive either intravenous paracetamol (15 mg/kg) or intravenous diclofenac sodium (1.5 mg/kg) 30 minutes before the end of surgery and postoperatively at 12-hour intervals up to 48 hours. The analgesic efficacy of diclofenac and paracetamol was assessed using the Numerical Rating Scale (NRS) score at 12, 24, and 48 hours after surgery. We also examined the need for rescue analgesia, coagulation profiles using a Sonoclot analyzer, and incidence of intracranial hematoma formation. Results: At 24 hours postsurgery, NRS scores were lower in group D than in group P; median (interquartile range) and mean rank NRS score in group D was 3.00 (1.0), 43.71, respectively, compared with 3.00 (1.0), 59.29 in group P (P=0.004). Patients in group P received more rescue analgesia than those in group D. Coagulation profiles were similar between groups at 24 hours. Activated clotting time was longer in group D (128.76±12.61 s) than in group P (123.84±09.77 s; P=0.03) at 48 hours, although remained within normal limits in both groups; clot rate and platelet function were similar at 48 hours. There was no difference in the incidence of postoperative tumor bed hematoma. Conclusion: Compared with paracetamol, diclofenac sodium provided more effective postoperative analgesia at 24 hours with no evidence of adverse effects on coagulation profiles in patients undergoing craniotomy for supratentorial tumors.

1 May 2020 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
ASAjay Singh
Ajay Singh
BNB. Naveen Naik
B. Naveen Naik
SSShiv Lal Soni
Shiv Lal Soni
GPG. D. Puri
G. D. Puri

11 December 2021 in Cureus
Verified
Journal Article
Open access
NNNaveen B. Naik
Naveen B. Naik
GPGoverdhan D. Puri
Goverdhan D. Puri
KKKamal Kajal
Kamal Kajal
VMVarun Mahajan
Varun Mahajan
ABAshish Bhalla
Ashish Bhalla
SSShiv Lal Soni
Shiv Lal Soni
Recent randomized controlled trials (RCTs) have indicated potential therapeutic benefits with high-dose dexamethasone (HDD) or tocilizumab (TCZ) plus standard care in moderate to severe coronavirus disease 2019 (COVID-19) with acute respiratory distress syndrome (ARDS). No study has compared these two against each other. We aimed to compare the efficacy and safety of HDD against TCZ in moderate to severe COVID-ARDS. Patients admitted with moderate to severe COVID-19 ARDS with clinical worsening within 48 hours of standard care were randomly assigned to receive either HDD or TCZ plus standard care. The primary outcome was ventilator-free days (VFDs) at 28 days. The main secondary outcomes were 28-day all-cause mortality and the incidence of adverse events. Our initial plan was to perform an interim analysis of the first 42 patients. VFDs were significantly lower in the HDD arm (median difference: 28 days; 95% confidence interval (CI): 19.35-36.65; Cohen’s d = 1.14; p < 0.001). We stopped the trial at the first interim analysis due to high 28-day mortality in the HDD arm (relative risk (RR) of death: 6.5; p = 0.007; NNT (harm) = 1.91). The incidence of secondary infections was also significantly high in the HDD arm (RR: 5.5; p = 0.015; NNT (harm) = 2.33). In our study population, HDD was associated with a very high rate of mortality and adverse events. We would not recommend HDD to mitigate the cytokine storm in moderate to severe COVID-19 ARDS. TCZ appears to be a much better and safer alternative.